Research programme: anticancer peptide aptamers - Aptanomics SA

Drug Profile

Research programme: anticancer peptide aptamers - Aptanomics SA

Alternative Names: AP 1; AP 2; AP 3; Aptamers

Latest Information Update: 06 Nov 2006

Price : $50

At a glance

  • Originator Aptanomics
  • Class Peptide aptamers; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2006 This programme is still in active development
  • 25 Mar 2004 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top